Overview

Intravitreal (IVT) Injectables Market is poised to value over USD 20 billion by 2029 end at a CAGR of over 6% during the forecast period 2021 to 2029.

Intravitreal injection involves injecting a fine needle into the eye to inject drugs into the eyeball. These drugs will then be applied directly to the vitreous humor. There are some eye diseases that can be treated with this drug, such as age-related macular degeneration (AMD), diabetic retinopathy, and infections inside the eye like endophthalmitis. Compared to topical administration, this method allows for more targeted delivery of medications because the needle can pass directly through the anatomical barrier (e.g. cornea, conjunctiva, and lens) and dynamic barrier (e.g. tears and aqueous humor). It could also minimize adverse drug effects to other body tissues via systemic circulation, which could be a risk from an intravenous injection of medications. It is possible for infections or other complications to occur during injections, but with the appropriate precautions throughout the process, the chances for these complications to occur can be reduced.

Vitreo-retinal disease is a leading cause of blindness and vision impairment across the world. Retinal problems affect millions of individuals worldwide, frequently resulting in vision loss or blindness. Age-related macular degeneration, diabetic macular edoema, diabetic retinopathy, and other retinal degenerative illnesses are frequent.

More than 70 million people suffer from age-related macular degeneration, according to the most recent numbers acquired throughout the study. Intravitreal (IVT) injectables are an important part of the therapy of retinal diseases. Patients with chronic retinal illnesses frequently require many doses of intravitreal (IVT) injectables, hence the intravitreal (IVT) injectables market is expected to increase rapidly over the projected period.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Intravitreal (IVT) Injectables Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Intravitreal (IVT) Injectables Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Intravitreal (IVT) Injectables Market:
• Alcon Pharmaceuticals
• Novartis  
• Regeneron Pharmaceuticals Inc.
• Allergan
• Alimera Sciences
• Bristol Myers Squibb
• Bausch & Lomb
• F. Hoffmann-La Roche
• Thrombogenics 
• Valeant Pharmaceuticals International
(Note: The list of the major players will be updated with the latest market scenario and trends)

Intravitreal (IVT) Injectables Market Segmentation:
By Drug Class
• Anti-VEGF
• Antibiotics
• Corticosteroids
• Antifungals
• Antivirals
By Indication 
• Diabetic Retinopathy
• Macular Degeneration
• Endophthalmitis
• Retinal Vein Occlusions
By Distribution Channel 
• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Online Pharmacies
By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Intravitreal (IVT) Injectables Market Sample:

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Intravitreal (IVT) Injectables Market By Drug Class, By Indication, By Distribution Channel and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- Targeted Antigen launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
   1.1. Objectives of the Study 
   1.2. Market Definition 
   1.3. Market Scope 
        1.3.1. Years Considered for the Study
        1.3.2. Market Covered
   1.4. Currency 
   1.5. Limitations 
   1.6. Stakeholders 

2. Research Methodology 
   2.1. Research Data 
        2.1.1. Secondary Data
               2.1.1.1. Key Data from Secondary Sources
        2.1.2. Primary Data
               2.1.2.1. Key Data from Primary Sources
   2.2. Market Size Estimation 
   2.3. Market Breakdown and Data Triangulation 
   2.4. Assumptions for the Study  

3. Executive Summary
   3.1. Market Outlook
   3.2. Segment Outlook
   3.3. Competitive Insights

4. Global Intravitreal (IVT) Injectables Market Variables, Trends & Scope
   4.1. Market Lineage Outlook
   4.2. Penetration and Growth Prospect Mapping
   4.3. Industry Value Chain Analysis
   4.4. Cost Analysis Breakdown
   4.5. Technology Overview
   4.6. Regulatory Framework
        4.6.1. Reimbursement Framework
        4.6.2. Standards and Compliances

5. Market Overview
   5.1. Market Dynamics
        5.1.1. Market Driver Analysis
               5.1.1.1. Increasing focus of Intravitreal (IVT) Injectables Market Companies on Brand Protection
               5.1.1.2. Untapped Opportunities in Emerging Regions
        5.1.2. Market Restraint Analysis
               5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
        5.1.3. Industry Challenges
               5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Intravitreal (IVT) Injectables Market Analysis Tools
   6.1. Industry Analysis - Porter’s
        6.1.1. Supplier Power
        6.1.2. Buyer Power
        6.1.3. Substitution Threat
        6.1.4. Threat from New Entrants
        6.1.5. Competitive Rivalry
   6.2. Pestel Analysis
        6.2.1. Political Landscape
        6.2.2. Environmental Landscape
        6.2.3. Social Landscape
        6.2.4. Technology Landscape
        6.2.5. Legal Landscape
   6.3. Major Deals And Strategic Alliances Analysis
        6.3.1. Joint Ventures
        6.3.2. Mergers and Acquisitions
        6.3.3. Licensing and Partnership
        6.3.4. Technology Collaborations
        6.3.5. Strategic Divestments
   6.4. Market Entry Strategies
   6.5. Case Studies

7. Global Intravitreal (IVT) Injectables Market, By Drug Class Historical Analysis and Forecast 2021-2029 (USD Million)
   7.1. Anti-VEGF
   7.2. Antibiotics
   7.3. Corticosteroids
   7.4. Antifungals
   7.5. Antivirals

8. Global Intravitreal (IVT) Injectables Market, By Indication Historical Analysis and Forecast 2021-2029 (USD Million)  
   8.1. Diabetic Retinopathy
   8.2. Macular Degeneration
   8.3. Endophthalmitis
   8.4. Retinal Vein Occlusions

9. Global Intravitreal (IVT) Injectables Market, By Distribution Channel Historical Analysis and Forecast 2021-2029 (USD Million)  
   9.1. Hospital Pharmacies
   9.2. Retail Pharmacies
   9.3. Drug Stores
   9.4. Online Pharmacies

10. North America Intravitreal (IVT) Injectables Market Analysis 2016-2020 and Forecast 2021-2029 (USD Million)
    10.1. Introduction
    10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          10.2.1. U.S.A
          10.2.2. Canada
          10.2.3. Mexico
    10.3. Market Size (USD Million) Forecast for North America 2021-2029

11. Latin America Intravitreal (IVT) Injectables Market Analysis 2016-2020 and Forecast 2021-2029 (USD Million)
    11.1. Introduction
    11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          11.2.1. Brazil
          11.2.2. Venezuela
          11.2.3. Argentina
          11.2.4. Rest of Latin America
    11.3. Market Size (USD Million) Forecast for Latin America 2021-2029

12. Europe Intravitreal (IVT) Injectables Market Analysis 2016-2020 and Forecast 2021-2029 (USD Million)
    12.1. Introduction
    12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          12.2.1. Germany
          12.2.2. U.K         
          12.2.3. France
          12.2.4. Italy
          12.2.5. Spain
          12.2.6. Russia
          12.2.7. Poland
          12.2.8. Rest of Europe
    12.3. Market Size (USD Million) Forecast for Europe 2021-2029

13. Asia Pacific Intravitreal (IVT) Injectables Market Analysis 2016-2020 and Forecast 2021-2029 (USD Million)
    13.1. Introduction
    13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          13.2.1. Japan
          13.2.2. China
          13.2.3. India
          13.2.4. Australia and New Zealand
          13.2.5. ASEAN
          13.2.6. Rest of Asia Pacific
    13.3. Market Size (USD Million) Forecast for Asia Pacific 2021-2029  

14. Middle East and Africa Market Analysis 2016-2020 and Forecast 2021-2029 (USD Million)
    14.1. Introduction
    14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          14.2.1. Saudi Arabia
          14.2.2. UAE
          14.2.3. South Africa
          14.2.4. Egypt
    14.3. Market Size (USD Million) Forecast for MEA 2021-2029

15. Market Share Analysis and Competitive Landscape   
    15.1. Global Landscape - Key Players, Revenue and Presence
    15.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
    15.3. Global Emerging Companies
    15.4. North America - Market Share Analysis and Key Regional Players
    15.5. Europe - Market Share Analysis and Key Regional Players
    15.6. Asia Pacific - Market Share Analysis and Key Regional Players
    15.7. Global Key Player - Growth Matrix

16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Targeted Antigens Offered and Financial Layouts)
    16.1. Alcon Pharmaceuticals
          16.1.1. Company Overview
          16.1.2. Product Portfolio
          16.1.3. SWOT Analysis
          16.1.4. Financial Overview
          16.1.5. Strategic Overview
    16.2. Novartis  
          16.2.1. Company Overview
          16.2.2. Product Portfolio
          16.2.3. SWOT Analysis
          16.2.4. Financial Overview
          16.2.5. Strategic Overview 
    16.3. Regeneron Pharmaceuticals Inc.
          16.3.1. Company Overview
          16.3.2. Product Portfolio
          16.3.3. SWOT Analysis
          16.3.4. Financial Overview
          16.3.5. Strategic Overview
    16.4. Allergan
          16.4.1. Company Overview
          16.4.2. Product Portfolio
          16.4.3. SWOT Analysis
          16.4.4. Financial Overview
          16.4.5. Strategic Overview
    16.5. Alimera Sciences
          16.5.1. Company Overview
          16.5.2. Product Portfolio
          16.5.3. SWOT Analysis
          16.5.4. Financial Overview
          16.5.5. Strategic Overview          
    16.6. Bristol Myers Squibb
          16.6.1. Company Overview
          16.6.2. Product Portfolio
          16.6.3. SWOT Analysis
          16.6.4. Financial Overview
          16.6.5. Strategic Overview      
    16.7. Bausch & Lomb
          16.7.1. Company Overview
          16.7.2. Product Portfolio
          16.7.3. SWOT Analysis
          16.7.4. Financial Overview
          16.7.5. Strategic Overview
    16.8. F. Hoffmann-La Roche
          16.8.1. Company Overview
          16.8.2. Product Portfolio
          16.8.3. SWOT Analysis
          16.8.4. Financial Overview
          16.8.5. Strategic Overview 
    16.9. Thrombogenics 
          16.9.1. Company Overview
          16.9.2. Product Portfolio
          16.9.3. SWOT Analysis
          16.9.4. Financial Overview
          16.9.5. Strategic Overview 
    16.10.Valeant Pharmaceuticals International
          16.10.1. Company Overview
          16.10.2. Product Portfolio
          16.10.3. SWOT Analysis
          16.10.4. Financial Overview
          16.10.5. Strategic Overview 

17. Pre and Post COVID-19 Impact
    17.1. Positive influence on the healthcare industry
    17.2. The financial disruption of the manufacturing sector
    17.3. Impact of COVID-19 on emerging companies
    17.4. Significant mandates in the healthcare regulations initiated by administrations
    17.5. The overall economic slowdown of the developing and developed nations

18. FutureWise SME Key Takeaway Points for Client

Tables

Figures